InspireMD receives Nasdaq minimum bid price deficiency notice
InspireMD received a notice from Nasdaq on July 17, 2026 that it failed to maintain the minimum $1.00 per share bid price required for continued listing on The Nasdaq Capital Market. The company has a 180-calendar-day compliance period until January 13, 2027 to regain compliance by achieving a closing bid price of at least $1.00 per share for ten consecutive business days. The company's common stock will continue trading on Nasdaq during the compliance period, and the company is evaluating options including a potential reverse stock split to restore compliance.
- Minimum bid price requirement: $1.00 per share under Nasdaq Listing Rule 5550(a)(2)
- Compliance period: 180 calendar days until January 13, 2027
- Deficiency measurement period: 30 consecutive business days from June 3, 2026 through July 16, 2026
- Cure standard: closing bid price of at least $1.00 per share for a minimum of ten consecutive business days
- Potential secondary compliance period: additional 180 calendar days if company satisfies other listing standards and provides written notice to Nasdaq
InspireMD has 180 days to restore its stock price above $1.00 per share or face potential delisting from The Nasdaq Capital Market; failure to cure could result in a Nasdaq delisting notice, though the company would have appeal rights to a Nasdaq Hearings Panel.
Derived from 8-K filed 2026-07-23. Not investment advice. Figures are extracted from the filing; prose is AI-assisted. View the source filing on SEC.gov →